(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 66.17% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.21%.
Rhythm Pharmaceuticals's revenue in 2026 is $189,757,000.On average, 18 Wall Street analysts forecast RYTM's revenue for 2026 to be $20,128,380,946, with the lowest RYTM revenue forecast at $17,599,785,952, and the highest RYTM revenue forecast at $22,574,351,043. On average, 17 Wall Street analysts forecast RYTM's revenue for 2027 to be $37,450,246,789, with the lowest RYTM revenue forecast at $29,109,912,126, and the highest RYTM revenue forecast at $44,604,470,325.
In 2028, RYTM is forecast to generate $60,698,571,167 in revenue, with the lowest revenue forecast at $43,497,569,843 and the highest revenue forecast at $82,624,897,190.